The NCI-H23 NSCLC cell line was used as a control and was known to be highly sensitive to ceralasertib monotherapy which has been attributed to an ATM-loss DDR-defect11,17 and growth inhibition could not be further increased when combined with IFN-β nor abrogated by IFNAR1 knockdown. The gene discussed is ATM; the disease is non-small cell lung carcinoma.